文献速递肿瘤 PET/CT核素与放射性配体治疗

ICOS靶向肽PET成像评估肺腺癌STING激动剂治疗反应

ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma.
PubMed 文献 · J Nucl Med · 2026-07-01

该研究通过多组学数据提出ICOS作为癌症免疫治疗影像生物标志物,并开发了靶向人ICOS的肽类PET示踪剂68Ga-DOTA-ICOSpep。在人源化A549肺腺癌小鼠模型中,68Ga-DOTA-ICOSpep PET可高特异性捕获ICOS阳性活化T细胞,并精准评估STING激动剂引起的治疗反应及促炎细胞因子释放增加。

要点

  • 68Ga-DOTA-ICOSpep PET可高特异性显像ICOS阳性活化T细胞。
  • ICOS PET能精准评估STING激动剂在肺腺癌中的治疗反应。
  • ICOS是有潜力的免疫反应生物标志物,可用于预测和监测免疫治疗疗效。

核心结论

  • ICOS PET成像能够精准评估STING激动剂诱导的治疗反应及促炎细胞因子释放增加。
  • ICOS是评估免疫反应的稳健生物标志物,68Ga-DOTA-ICOSpep PET是预测和监测肺腺癌免疫治疗效果的可靠工具。

研究设计与样本

  • 研究通过多组学数据集描述诱导性共刺激分子(ICOS)作为评估癌症免疫治疗的潜在影像生物标志物。
  • 开发了靶向人ICOS的新型肽类PET示踪剂68Ga-DOTA-ICOSpep。
  • 采用流式细胞术和免疫荧光表征ICOS表达模式。
  • 在人源化A549细胞系来源的小鼠模型中,给予环鸟苷单磷酸-腺苷单磷酸和diABZI STING激动剂治疗,进行68Ga-DOTA-ICOSpep PET成像和细胞因子检测。

主要发现

  • 68Ga-DOTA-ICOSpep在体内可高特异性捕获人ICOS阳性活化T细胞。
  • 该特异性通过肿瘤PET感兴趣区定量与ICOS免疫组化染色之间的线性回归分析以及CD3耗竭研究得到验证。

临床怎么用

  • ICOS PET成像可用于精准评估肺腺癌患者对STING激动剂等免疫治疗的反应。
  • 68Ga-DOTA-ICOSpep PET可作为预测和监测癌症免疫治疗疗效的可靠工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The innovation of cancer immunotherapy is improving clinical theranostics for lung cancer. Given the variation of therapeutic effects among patients, there is an urgent need to develop novel tools for precisely evaluating immune responses. Methods: Herein, we first described the potential of the inducible costimulator (ICOS) as a promising imaging biomarker for assessing cancer immunotherapy through multiple omics datasets and subsequently developed 68Ga-DOTA-ICOSpep, a novel peptide-based PET tracer targeting human ICOS. We characterized ICOS expression patterns via flow cytometry and immunofluorescence and performed 68Ga-DOTA-ICOSpep PET imaging and cytokine testing on humanized A549 cell line-derived mouse models receiving cyclic guanosine monophosphate-adenosine monophosphate and diABZI stimulator of interferon genes (STING) agonist treatment. Results: 68Ga-DOTA-ICOSpep could capture human ICOS-positive activated T cells with high specificity in vivo, which was validated via linear regression analysis between tumor PET region-of-interest quantifications against ICOS immunohistochemistry staining as well as a CD3 depletion study. Conclusion: ICOS PET imaging enabled precise evaluation of therapeutic responses and increased proinflammatory cytokine release induced by the STING agonist. Our data demonstrated that ICOS is a robust biomarker for assessing immune responses, and 68Ga-DOTA-ICOSpep PET imaging is a reliable tool for predicting and monitoring therapeutic effects of cancer immunotherapy in lung adenocarcinoma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Duan S, Tan B, Mao Y, et al. ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma. J Nucl Med. 2026. PMID: 41991338. doi:10.2967/jnumed.125.271193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。